Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

22 Apr 2020

Abstract excerpt

Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple myeloma (MM). CD38-directed antibodies have several mechanisms of action. Fc-dependent immune effector mechanisms include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis. In addition, direct effects and immunomodulatory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32331242
DOI: 10.3390/jcm9041195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaPMID 32331242Read ↗

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabSemantic proximity Read ↗

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literatureSemantic proximity Read ↗

Resistance to proteasome inhibitors and other targeted therapies in myeloma.Semantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

Molecular and immunological mechanisms of clonal evolution in multiple myelomaSemantic proximity Read ↗

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaSemantic proximity Read ↗

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.